Reprogram Biosciences is a preclinical oncology biotechnology company in San Carlos, California, founded in 2025. It develops mRNA-based therapeutics that reprogram solid-tumor cells in situ, using lipid nanoparticle delivery of gene cocktails injected directly into the tumor to induce antigen-presenting function in the cancer cells themselves. The intent is to turn an immunosuppressive tumor microenvironment into a site of immune activation and drive a systemic antitumor response. The company has raised $6 million in seed capital from Unshackled Ventures, 1517 Fund and Narya.